Table 1.

The efficacy of oromucosal spray nabixiomol, oral dronabinol, and oral nabilone forms of cannabis on MS-related symptoms and their adverse effects.

Cannabinoid Agents	Therapeutic Actions	Adverse Effects
Nabiximols	Significant improvement in MS-related spasticity, pain, and sleep problems. Minor effect on the alleviation of bladder dysfunctions in MS patients and favorable effects but statistically insignificant effects onHRQoL. Unsuccessful in the treatment of MS-related tremors and ataxia and no significant changes in terms of disability and progression was shown in MS patients.	Moderate with the most commonly reported adverse effects: dizziness, fatigue, drowsiness, vertigo, and dry mouth.
Dronabinol	Highly effective in the treatment of pain in MS patients. Significant improvement in MS sleep problems. Other symptoms showed only little improvement or no effect.	Mild to moderate adverse effects: dizziness, dry mouth, and weariness.
Nabilone	Beneficial effects in lowering most MS symptoms, including spasticity, pain, bladder dysfunction, and quality of life. No significant effects on tremors. No clinical investigation on the symptoms of MS sleep problems and MS-related disability and progression.	Mild to moderateadverse effects: dizziness, dry mouth, weariness, and asthenia.